Report period | 2019 | 2020 | 2021 | 2022 | 2023 | Q2 24 |
---|---|---|---|---|---|---|
End date of the reporting period | ||||||
Capitalization, $ | ||||||
Capitalization, $ | ||||||
Enterprise Value | ||||||
Book Value | ||||||
Shareholders Book Value | ||||||
Current liabilities | ||||||
Noncurrent liabilities | ||||||
Total liabilities | ||||||
Debt | ||||||
Cash and cash equivalents | ||||||
Net debt | ||||||
Assets | ||||||
Total ordinary shares | ||||||
Ordinary share price |
Ticker | Name | Type | Nominal value | ISIN | Price |
---|---|---|---|---|---|
MRVI:US | Maravai LifeSciences Holdings | Common share | - | US56600D1072 | $8.76 |
Company name | Maravai LifeSciences Holdings |
---|---|
Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Life Sciences Tools & Services / Life Sciences Tools & Services |
Business address | 10770 Wateridge Circle Suite 200 San Diego, CA 92121 United States |
Mailing address | 10770 Wateridge Circle Suite 200 San Diego, CA 92121 United States |
Website | investors.maravai.com |
Information disclosure | www.sec.gov |